ERBB2 and breast cancer: In summary, this novel large scope in silico analysis highlights further the potential of ENO1 as a novel biomarker of BC progression, particularly in the triple-negative/basal subtype, a subtype with worse prognosis than the hormone-positive and the HER2-positive subtypes.